Work

A randomized, open-label comparison of lorlatinib versus crizotinib as first-line treatment for advanced anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer

Year: 2017

Type: article

Study design: Clinical Trial

Source: Annals of Oncology

DOI: 10.1093/annonc/mdx380.081

Authors: A.T. Shaw, T.M. Bauer, T. Takahashi, C.S. Baik, A. Polli, M. Carpentieri, J-F. Martini, B.J. Solomon

Institutions: Massachusetts General Hospital, Sarah Cannon, Shizuoka Cancer Center, Seattle Cancer Care Alliance, University of Washington, Pfizer (Italy), Pfizer (United States), Peter MacCallum Cancer Centre

Language: English

Topic: Lung Cancer Treatments and Mutations

Subfield: Pulmonary and Respiratory Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: bronze

OpenAlex ID: W2761226474

FWCI:

Cites:

Cited by: 1

Related to: 10